Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products. The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide. Read More
Cannabis company Tilray Brands (NASDAQ:TLRY) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $209.5 million. Its non-GAAP loss of $0 per share increased from -$0.04 in the same quarter last year.
Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net Cash Used in Operations Improved by $34 Million Year-Over-Year
The cannabis market reacted big time to Trump's re-posting of a pro-CBD video that highlighted CBD’s potential to reduce aging-related ailments and replace costly pharmaceuticals. In addition, Tilray announced significant international expansion.
Stocks shrugged off the government shutdown by hitting record highs; the focus now turns to the upcoming earnings season, which will likely lead stocks higher.
Looking back on beverages, alcohol, and tobacco stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Coca-Cola (NYSE:KO) and its peers.
A number of stocks fell in the afternoon session after signs of weakening consumer health and a cautious outlook for the upcoming holiday season emerged.
